Johnson & Johnson (FRA:JNJ)
Germany · Delayed Price · Currency is EUR | Market Cap | 363.66B |
| Revenue (ttm) | 77.35B |
| Net Income (ttm) | 19.34B |
| Shares Out | n/a |
| EPS (ttm) | 7.97 |
| PE Ratio | 18.80 |
| Forward PE | 16.19 |
| Dividend | 4.62 (3.06%) |
| Ex-Dividend Date | Aug 26, 2025 |
| Volume | 11,156 |
| Average Volume | 4,343 |
| Open | 152.08 |
| Previous Close | 151.96 |
| Day's Range | 150.52 - 152.12 |
| 52-Week Range | 128.16 - 161.30 |
| Beta | n/a |
| RSI | 54.08 |
| Earnings Date | Oct 14, 2025 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial numbers in USD Financial StatementsNews
Johnson & Johnson (JNJ) Welcomes New Board Member, John Morikis
Johnson & Johnson (JNJ) Welcomes New Board Member, John Morikis
Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors
Johnson & Johnson (NYSE: JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. Th...
Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been...
Johnson & Johnson to Present at Bernstein 2nd Annual Healthcare Forum | JNJ stock news
Johnson & Johnson to Present at Bernstein 2nd Annual Healthcare Forum | JNJ stock news
Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bernstein 2nd Annual Healthcare Forum on Wednesday, September 24th, 2025. Management will participate in a Fires...
Johnson & Johnson: All-Time Highs In Sight After Raised Guidance And A Technical Breakout
Johnson & Johnson: A Safe Hold, But Lacking Catalysts To Beat The Market
Johnson & Johnson (JNJ) Highlights Promising Lung Cancer Treatment Study
Johnson & Johnson (JNJ) Highlights Promising Lung Cancer Treatment Study
Johnson & Johnson's Groundbreaking Lung Cancer Treatment Shows Promising Results | JNJ ...
Johnson & Johnson's Groundbreaking Lung Cancer Treatment Shows Promising Results | JNJ stock news
Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer
Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one year RAR...
Johnson & Johnson: A 6.9 Rating and What It Means for Investors
What does the future hold for Johnson & Johnson? In this episode, we break down the company's strengths, challenges, and what investors can expect moving forward.
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer
RYBREVANT® combination extends survival and significantly reduces common EGFR and MET resistance mutations seen with osimertinib-based treatment BARCELONA, Spain , Sept. 6, 2025 /PRNewswire/ -- Johnso...
September Dogs Of The Dow Unleash One Ideal 'Safer' DiviDog
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are well-covered. Analyst forecasts suggest top Dow Dogs could de...
JNJ Faces Scrutiny Over Tylenol's Alleged Autism Link
JNJ Faces Scrutiny Over Tylenol's Alleged Autism Link
JNJ Shares Decline Following Autism Report Involving Tylenol
JNJ Shares Decline Following Autism Report Involving Tylenol
P/E Ratio Insights for Johnson & Johnson
In the current market session, Johnson & Johnson Inc. (NYSE: JNJ) stock price is at $177.33, after a 0.80% drop. However, over the past month, the company's stock spiked by 2.31% , and in the past ye...
Johnson & Johnson Announces Upcoming 3rd Quarter Earnings Call | JNJ stock news
Johnson & Johnson Announces Upcoming 3rd Quarter Earnings Call | JNJ stock news
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 14th to review third-quarter results. Joaquin Duato, Chairman and Chief Executiv...
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 14th to review third-quarter results. Joaq...
Johnson & Johnson (JNJ) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Johnson & Johnson Unveils Results from the VARIPURE Substudy of SECURE, a Real-World Study on VARIPULSE™ Platform, at 2025 European Society of Cardiology (ESC) Congress
VARIPURE demonstrated strong safety outcomes with no incidence of stroke and 99.7% acute effectiveness of the VARIPULSE ™ Platform in nearly 800 enrolled patientsi IRVINE, Calif. , Sept. 2, 2025 /PRNe...
Johnson & Johnson's Impella CP Heart Pump Shows Long-Term Survival Benefits | JNJ stock news
Johnson & Johnson's Impella CP Heart Pump Shows Long-Term Survival Benefits | JNJ stock news
New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump
MADRID , Aug. 31, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously publ...
Johnson & Johnson Ends Rheumatoid Arthritis Drug Combo Program
Johnson & Johnson ended a Phase 2a study ... Full story available on Benzinga.com